Genetic Testing: Ready, Set … Actionable?

In June 2000, President Bill Clinton announced that the international Human Genome Project and Celera Genomics had completed the initial sequencing of the human genome. This landmark accomplishment cost an estimated $2.7 billion.1 Nearly...

Online Exclusives

FDA Proposes Adding Drug Prices to Advertising

The U.S. Food and Drug Administration’s (FDA’s) proposal to require pharmaceutical companies to include drug prices in consumer advertising has led to more questions...

Insurers and Physicians Clash Over “Avoidable Visits”

Anthem, one of the largest health insurance companies in the U.S., is coming under fire for denying patients’ claims for emergency room visits for...

News

From the Blood Journals

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...

Multimedia

Pulling Back the Curtain: Brian J. Bolwell, MD

Hear more from our interview with Dr. Bolwell, where he shares what he looks for in new recruits and who his dream dinner party guest...

Pulling Back the Curtain: Olatoyosi Odenike, MD

Hear more from our interview with Dr. Odenike, where she describes finding her home in hematology, and offers advice for early-career doctors.

Big Questions, Tough Answers: Norman “Ned” Sharpless, MD

In more from our interview, Dr. Sharpless shares his vision as National Cancer Institute Director and for overcoming the obstacles to advancing research.

Pulling Back the Curtain: Andra James, MD, MPH

Hear more from our interview with Dr. James, where she shares more about the patients who inspired her to pursue hematology and the importance...

On Location

A Curative Strategy for High-Risk Smoldering Multiple Myeloma?

In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the...

Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma

Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade,...

Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple...

Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095

More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from...

BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma

In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of...

Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL

Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients...

Latest Headlines

Advertisement

ASH Directions

ASH Announces Partnership to Foster Genomic Research, The Hematologist Debuts Two New Departments, and...

ASH Programs Promoting Advocacy and Translational Research Now Accepting Nominations Advocacy Leadership Institute The American Society of Hematology (ASH) is now accepting nominations for...

Roundtable Discussion With Senator Booker, The Hematologist App Now Available, and more

ASH Participates in Roundtable Discussion With Senator Booker On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease...

Sign up for our
eNewsletter!

Stand Up To Cancer Funds AI Research, Damon Runyon Cancer Research Foundation Research Fellows...

Remembering Barry Paw (1961-2017) Barry Paw, MD, PhD, a principal investigator and pediatric oncologist at Brigham and Women’s Hospital and Dana-Farber/Boston Children’s Cancer and Blood...

Remembering Ihor R. Lemischka and Günter Blobel, Feinstein Institute Researcher Awarded NIH Grant, and...

Remembering Ihor R. Lemischka (1953-2017) Ihor R. Lemischka, PhD, a pioneer in the fields of hematopoiesis and pluripotent cell biology, died on December 17, 2017.Dr....

Mohamad Cherry Joins Atlantic Health System, Remembering Eliezer A. Rachmilewitz, and more

Remembering Eliezer A. Rachmilewitz, MD Eliezer A. Rachmilewitz, MD, professor emeritus of medicine at the Hebrew University Hadassah Medical School in Jerusalem, died on December...

Genetic Testing: Ready, Set … Actionable?

In June 2000, President Bill Clinton announced that the international Human Genome Project and Celera Genomics had completed the initial sequencing of the human...

Exploring the Boundaries of Drug Importation

Importing pharmaceuticals from other countries to access lower-cost medicines is still a relatively murky issue. Hematologist Kenneth R. Adler, MD, of Summit Medical Group MD...

Myeloid Malignancies: The Next Frontier for Immunotherapy

Building on the success of chimeric antigen receptor (CAR) T-cell therapies in lymphocytic leukemia and certain lymphomas – and the advances seen with checkpoint...